Additionally, the potential of emerging immune checkpoints, such as TIM-3, TIGIT, LAG-3, and CD47, in BC remains unexplored, raising the need for further investigation into their roles and therapeutic applications. This evidence concerns the gene HAVCR2 and breast cancer.